Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances

28 Feb 2023

Abstract excerpt

CDKN2A is a tumor suppressor gene encoding the p16 protein, a key regulator of the cell cycle. CDKN2A homozygous deletion is a central prognostic factor for numerous tumors and can be detected by several techniques. This study aims to evaluate the extent to which immunohistochemical levels of p16 expression may provide information about CDKN2A deletion. A retrospective study was conducted in 173 gliomas of all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Glioma Diagnosis and Treatment
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36900302
DOI: 10.3390/cancers15051512

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic SignificancesPMID 36900302Read ↗

Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.Semantic proximity Read ↗

Assessment of CDKN2A homozygous and heterozygous deletions in gliomas across multiple detection platformsSemantic proximity Read ↗

CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistrySemantic proximity Read ↗

CDKN2A/p16 inactivation in the prognosis of oligodendrogliomasSemantic proximity Read ↗

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.Semantic proximity Read ↗

Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.Semantic proximity Read ↗

Correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4A genes in astrocytomas.Semantic proximity Read ↗

Loss of P16INK4 expression is frequent in high grade gliomas.Semantic proximity Read ↗

p14ARF deletion and methylation in genetic pathways to glioblastomas.Semantic proximity Read ↗

[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].Semantic proximity Read ↗

Integrated assessment of malignancy in IDH‐mutant astrocytoma with p16 and methylthioadenosine phosphorylase immunohistochemistrySemantic proximity Read ↗

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.